Bioengineering

ImaRx Therapeutics to Study Permeability of Blood-Brain Barrier Using Microbubbles & Ultrasound Under NIH Grant

Published in Medical Device Business Week, September 5th, 2007

ImaRx Therapeutics, Inc. (Nasdaq:IMRX) announced it has received an approximately $950,000 Phase I STTR grant from the National Institute of Neurological Disorders and Stroke, a division of the National Institutes of Health (NIH) to study changes in the permeability of the blood-brain barrier with targeted microbubbles and ultrasound over a two year period.

Although vital for normal brain function, blood-brain barrier impermeability presents a problem when treating malignant and degenerative disorders of the central nervous system, such as brain cancer, Alzheimer's and Parkinson's disease. Under the terms of this grant, ImaRx will evaluate whether microbubbles and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Business Week

Source: Medical Device Business Week (2007-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry